세계의 전립선암 시장에 대해 조사했으며, 시장의 개요와 출시 치료법, 파이프라인 동향, 향후 전망 등을 제공하고 있습니다.
목차
개요
현재 및 향후 치료 알고리즘
조사 목적
차세대 안드로겐 수용체 저해제
- 출시 약제
- Xtandi(enzalutamide; Astellas Pharma/Pfizer)
- Erleada(apalutamide; Johnson & Johnson)
- Nubeqa(darolutamide; Bayer/Orion)
신규 제제 안드로겐 제거 요법
- 출시 약제
- Orgovyx(relugolix; Sumitomo Pharma/Takeda)
PARP 저해제
- 출시 약제
- Rubraca(rucaparib; Pharmaand GmbH)
- Lynparza(olaparib; AstraZeneca)
- Talzenna(talazoparib; Pfizer)
- 파이프라인 약제
PD-1/PD-L1 체크포인트 저해제
- 파이프라인 약제
- Tecentriq(atezolizumab; Genentech/Roche)
- Keytruda(pembrolizumab; Merck & Co.)
방사선 요법
- 출시 약제
- Xofigo(2 염화 라듐 223, Bayer)
- Pluvicto(루테튬-177 PSMA 617, Novartis)
- 파이프라인 약제
- [Lu-177]-PNT2002(Lantheus/POINT Biopharma)
AKT 저해제
- 파이프라인 약제
- Truqap(capivasertib; AstraZeneca)
사이클린 의존성 키나아제 저해제
- 파이프라인 약제
- Verzenio(abemaciclib; Eli Lilly and Company)
향후 치료 동향
부록
KSA
Delve into the evolving landscape of prostate cancer treatment with insights from 12 key opinion leaders. This report explores the future of therapies like Xtandi, Erleada, and Orgovyx, the impact of PARP inhibitors, and the potential of novel treatments. Understand the challenges and opportunities in addressing unmet needs and the role of AI in advancing care.
Key questions answered:
- How is the use of Xtandi expected to evolve in the next three to five years?
- What is the clinical experience with Erleada, and how significant is its Phase III PROTEUS study?
- Can Orgovyx challenge conventional ADTs in clinical practice?
- How are PARP inhibitors impacting the treatment paradigm for prostate cancer
- What role might immune checkpoint inhibitors play in prostate cancer treatment?
- How significant is the approval of Pluvicto for metastatic prostate cancer, and what are its benefits over Xofigo?
Key brands covered in this report:
- Xtandi (enzalutamide)
- Erleada (apalutamide)
- Nubeqa (darolutamide)
- Orgovyx (relugolix)
- Rubraca (rucaparib)
- Lynparza (olaparib)
- Akeega (abiraterone acetate/niraparib)
- Talzenna (talazoparib)
|
- Saruparib
- Tecentriq (atezolizumab)
- Keytruda (pembrolizumab)
- Xofigo (radium-223 dichloride)
- Pluvicto (Lutetium-177 PSMA 617)
- [Lu-177]-PNT2002
- Truqap (capivasertib)
- Verzenio (abemaciclib
|
Companies:
- Novartis
- Lilly
- Roche
- AstraZeneca
- Pfizer
- Merck & Co.
- Genentech
- Astellas
|
- Takeda
- Bayer
- Orion Pharma
- Johnson & Johnson
- Lantheus
- pharma&
- Sumitomo Pharma America
- POINT Biopharma
|
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
Next-generation androgen receptor inhibitors
- Marketed drugs
- Xtandi (enzalutamide; Astellas Pharma/Pfizer)
- Erleada (apalutamide; Johnson & Johnson)
- Nubeqa (darolutamide; Bayer/Orion)
Novel formulation androgen-deprivation therapies
- Marketed drugs
- Orgovyx (relugolix; Sumitomo Pharma/Takeda)
PARP inhibitors
- Marketed drugs
- Rubraca (rucaparib; Pharmaand GmbH)
- Lynparza (olaparib; AstraZeneca)
- Talzenna (talazoparib; Pfizer)
- Pipeline drugs
PD-1/PD-L1 checkpoint inhibitors
- Pipeline drugs
- Tecentriq (atezolizumab; Genentech/Roche)
- Keytruda (pembrolizumab; Merck & Co.)
Radiation-based therapies
- Marketed drugs
- Xofigo (radium-223 dichloride; Bayer)
- Pluvicto (Lutetium-177 PSMA 617; Novartis)
- Pipeline drugs
- [Lu-177]-PNT2002 (Lantheus/POINT Biopharma)
AKT inhibitors
- Pipeline drugs
- Truqap (capivasertib; AstraZeneca)
Cyclin-dependent kinase inhibitors
- Pipeline drugs
- Verzenio (abemaciclib; Eli Lilly and Company)
Future treatment trends
Appendix
- KOL details
- KOLs from North America
- KOLs from Europe
